HTB

2009

Efavirenz conceptions in Soweto

Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg

A cost-effectiveness analysis of the OCTANE trial

The PEARL study

Results from HSV-2 acyclovir studies

Overview of TB-related studies at IAS

CD4 responses after viral suppression for more than 7 years on HAART

Raltegravir approved in Europe for treatment-naive patients

50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients

Raltegravir trough levels reduced by etravirine may require use of TDM

Lopinavir/r affects PK exposure of some antimalarial drugs

Darunavir/r increases exposure to nevirapine

Interaction between Ginkgo biloba and efavirenz

Use of raltegravir in HIV-positive transplant recipients

Trends in Immunology: free access issue on immune senescence

Low viral loads in elite controllers

Immune surveillance below the radar: study offers explanation for acyclovir’s failure to reduce HIV risk

Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption

Detention and removal of HIV-positive people in the UK

Letter: comment on swine flu algorithm

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts

Access to HCV treatment in Eastern Europe

Guide to HIV and hepatitis B coinfection

TAG pipeline report

New TB website and resource

Etravirine (Intelence) label change in the US due to severe hypersensitivity reactions

HIV and the kidneys

Video news: online resource

Volume 10 Number 9/10 September/October 2009 PDF

Volume 10 Number 7/8 July/August 2009

HIV swine flu triage tools and flowcharts

HIV and swine flu – patient leaflet

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes

Biomarkers associated with mortality: long-term follow up from SMART

Update on Interleukin-2 clinical trials

Influenza vaccine effective in HIV-positive adults

Reducing HIV transmission during breastfeeding

Treating children previously exposed to single dose nevirapine

10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination

Interactions between ARVs and antimalarials atovaquone and proguanil

Four weeks lopinavir/r to cover functional monotherapy when stopping HAART

Efavirenz-related studies: genetics, smoking and TDM

Atazanavir: a suitable case for TDM?

Raltegravir PK in blood plasma and the genital tract

A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission

Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding

Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

Bioavailability of Thai generic lopinavir/ritonavir

XVIII International Drug Resistance Workshop, 9-13 June 2009, Florida

Transmitted multidrug-resistant HIV persists in PBMC DNA for years

Low-level Q148R in people without integrase inhibitor experience

Cut-offs suggested for predicting efavirenz failure with low-level K103N

Lower M184V rates with FTC/TDF than with 3TC/TDF

HBV resistance to lamivudine at undetectable and low levels of viremia

Raltegravir approved in the US for treatment-naive patients: paranoia and anxiety added as side effects

UK (BHIVA) guidelines online for comment (2009)

TMC207 reduces time to sputum conversion in phase II trial on patients with drug-resistant TB

Maximum suppression: ART intensification does not reduce residual viral load

The role of Ad5-specific CD4 T-cells in enhancing risk of HIV acquisition in the Merck vaccine trial

Tracing HIV reservoirs

Illuminating early events in HIV infection using single genome amplification

Volume 10 Number 7/8 July/August 2009 PDF

Post navigation